ECULIZUMAB FOR ADULT PATIENTS WITH ATYPICAL HAEMOLYTIC-UREMIC SYNDROME: FULL DATASET ANALYSIS OF POST-MARKETING SURVEILLANCE IN JAPAN

被引：0

作者：

Maruyama, Shoichi ^{[1
]}

Ikeda, Yoichiro ^{[2
]}

Kaname, Shinya ^{[3
]}

Kato, Noritoshi ^{[1
]}

Matsumoto, Masanori ^{[4
]}

Ishikawa, Yumiko ^{[5
]}

Shimono, Akihiko ^{[5
]}

Miyakawa, Yoshitaka ^{[6
]}

Nangaku, Masaomi ^{[2
]}

Shibagaki, Yugo ^{[7
]}

Okada, Hirokazu ^{[6
]}

机构：

[1] Nagoya Univ, Dept Nephrol, Grad Sch Med, Nagoya, Aichi, Japan

[2] Univ Tokyo, Div Nephrol & Endocrinol, Tokyo, Japan

[3] Kyorin Univ, Dept Nephrol & Rheumatol, Sch Med, Tokyo, Japan

[4] Nara Med Univ, Dept Blood Transfus Med, Nara, Japan

[5] Alexion Pharma GK, Tokyo, Japan

[6] Saitama Med Univ, Dept Gen Internal Med, Saitama, Japan

[7] St Marianna Univ, Sch Med, Div Nephrol & Hypertens, Dept Med, Kawasaki, Kanagawa, Japan

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2022年 / 37卷

关键词：

D O I：

暂无

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

MO316

引用

页码：I231 / I232

页数：2

共 50 条

[1] Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan
Ito, Shuichi
Hataya, Hiroshi
Ashida, Akira
Hamada, Riku
Ishikawa, Tomoaki
Ishikawa, Yumiko
Shimono, Akihiko
Konomoto, Takao
Miyazawa, Tomoki
Ogura, Masao
Tanaka, Kazuki
Kagami, Shoji
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 (02) : 414 - 424
[2] Eculizumab for adult patients with atypical haemolytic-uraemic syndrome: full dataset analysis of Japanese post-marketing surveillance
Maruyama, Shoichi
Ikeda, Yoichiro
Kaname, Shinya
Kato, Noritoshi
Matsumoto, Masanori
Ishikawa, Yumiko
Shimono, Akihiko
Miyakawa, Yoshitaka
Nangaku, Masaomi
Shibagaki, Yugo
Okada, Hirokazu
[J]. JOURNAL OF NEPHROLOGY, 2024,
[3] Safety and effectiveness of eculizumab for adult patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance
Hideki Kato
Yoshitaka Miyakawa
Yoshihiko Hidaka
Norimitsu Inoue
Shuichi Ito
Shoji Kagami
Shinya Kaname
Masanori Matsumoto
Masashi Mizuno
Takahisa Matsuda
Akihiko Shimono
Shoichi Maruyama
Yoshihiro Fujimura
Masaomi Nangaku
Hirokazu Okada
[J]. Clinical and Experimental Nephrology, 2019, 23 : 65 - 75
[4] Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance
Kato, Hideki
Miyakawa, Yoshitaka
Hidaka, Yoshihiko
Inoue, Norimitsu
Ito, Shuichi
Kagami, Shoji
Kaname, Shinya
Matsumoto, Masanori
Mizuno, Masashi
Matsuda, Takahisa
Shimono, Akihiko
Maruyama, Shoichi
Fujimura, Yoshihiro
Nangaku, Masaomi
Okada, Hirokazu
[J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2019, 23 (01) : 65 - 75
[5] Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance
Shuichi Ito
Yoshihiko Hidaka
Norimitsu Inoue
Shinya Kaname
Hideki Kato
Masanori Matsumoto
Yoshitaka Miyakawa
Masashi Mizuno
Hirokazu Okada
Akihiko Shimono
Takahisa Matsuda
Shoichi Maruyama
Yoshihiro Fujimura
Masaomi Nangaku
Shoji Kagami
[J]. Clinical and Experimental Nephrology, 2019, 23 : 112 - 121
[6] Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance
Ito, Shuichi
Hidaka, Yoshihiko
Inoue, Norimitsu
Kaname, Shinya
Kato, Hideki
Matsumoto, Masanori
Miyakawa, Yoshitaka
Mizuno, Masashi
Okada, Hirokazu
Shimono, Akihiko
Matsuda, Takahisa
Maruyama, Shoichi
Fujimura, Yoshihiro
Nangaku, Masaomi
Kagami, Shoji
[J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2019, 23 (01) : 112 - 121
[7] Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan
Nishimura, Jun-ichi
Kawaguchi, Tatsuya
Ito, Shuichi
Murai, Hiroyuki
Shimono, Akihiko
Matsuda, Takahisa
Fukamizu, Yuji
Akiyama, Hirozumi
Hayashi, Hideo
Nakano, Takashi
Maruyama, Shoichi
[J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 118 (04) : 419 - 431
[8] Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan
Jun-ichi Nishimura
Tatsuya Kawaguchi
Shuichi Ito
Hiroyuki Murai
Akihiko Shimono
Takahisa Matsuda
Yuji Fukamizu
Hirozumi Akiyama
Hideo Hayashi
Takashi Nakano
Shoichi Maruyama
[J]. International Journal of Hematology, 2023, 118 : 419 - 431
[9] Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan
Ninomiya, Haruhiko
Obara, Naoshi
Chiba, Shigeru
Usuki, Kensuke
Nishiwaki, Kaichi
Matsumura, Itaru
Shichishima, Tsutomu
Okamoto, Shinichiro
Nishimura, Jun-ichi
Ohyashiki, Kazuma
Nakao, Shinji
Ando, Kiyoshi
Kanda, Yoshinobu
Kawaguchi, Tatsuya
Nakakuma, Hideki
Harada, Daisuke
Akiyama, Hirozumi
Kinoshita, Taroh
Ozawa, Keiya
Omine, Mitsuhiro
Kanakura, Yuzuru
[J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 104 (05) : 548 - 558
[10] Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan
Haruhiko Ninomiya
Naoshi Obara
Shigeru Chiba
Kensuke Usuki
Kaichi Nishiwaki
Itaru Matsumura
Tsutomu Shichishima
Shinichiro Okamoto
Jun-ichi Nishimura
Kazuma Ohyashiki
Shinji Nakao
Kiyoshi Ando
Yoshinobu Kanda
Tatsuya Kawaguchi
Hideki Nakakuma
Daisuke Harada
Hirozumi Akiyama
Taroh Kinoshita
Keiya Ozawa
Mitsuhiro Omine
Yuzuru Kanakura
[J]. International Journal of Hematology, 2016, 104 : 548 - 558

← 1 2 3 4 5 →